We evaluated the impact of genetic analysis combining cytogenetics and broad molecular screening on leukemia diagnosis according to World Health Organization (WHO) and on genetic risk assignment. A two-step nested multiplex RT-PCR assay was used that allowed the detection of 29 fusion transcripts. A total of 186 patients (104 males (56%), 174 adults (94%), 12 children (6%), 155 AML (83%), 31 ALL (17%)) characterized by morphology and immunophenotyping were included. Of these 186 patients, 120 (65%) had a genetic abnormality. Molecular typing revealed a fusion transcript in 49 (26%) patients and cytogenetic analysis revealed an abnormal karyotype in 119 (64%). A total of 27 (14%) cases were genetically classified as favorable, 107 (58%) intermediate and 52 (28%) unfavorable. For 38 (20%) patients, there was a discrepancy in the genetic risk assignments obtained from broad molecular screening and cytogenetics. Cryptic fusion transcripts in nine (5%) patients changed the genetic risk assignment in four and the WHO classification in four patients. In 34 patients (18%), cytogenetics defined the risk assignment by revealing structural and numerical chromosomal abnormalities not detected by molecular screening. Broad molecular screening and cytogenetics are complementary in the diagnosis and genetic risk assignment of acute leukemia.
Introduction
Molecular leukemias and chromosomal aberrations are hallmarks of acute leukemia. These have changed our approach to leukemic pathogenesis, 1 they have provided a basis for classification, as documented by the World Health Organization (WHO) Classification of Tumors of Haematopoietic and Lymphoid Tissues, 2 and they currently guide searches for targeted therapies. 3, 4 Therapeutic decision making is based on various well-defined prognostic parameters, the most important being the genetic makeup of the leukemic cell. 5, 6 The application of molecular analysis and cytogenetics for diagnosis and follow-up is controversial. The availabilities of the methods and the need to restrict costs greatly influence the requesting clinician in choosing the approach to genetic characterization. While molecular techniques such as reverse transcriptionpolymerase chain reaction (RT-PCR) and fluorescent in situ hybridization (FISH) enable efficient detection of targeted gene abnormalities, cytogenetics provides a comprehensive picture of chromosomal integrity in the leukemic cell without implicating specific genes. It is general practice to search by RT-PCR for AML1-ETO, CBFb-MYH11, PML-RARa in the case of AML, or for BCR-ABL, E2A-PBX1 and TEL-AML1 in the case of B-ALL. The detection of MLL rearrangements with various partner genes is more laborious. In most cases, a suggestive karyotype is a trigger to perform FISH analysis or Southern blotting. Furthermore, rare fusion transcripts are usually not sought in routine hematology laboratories. Cytogenetics reveals numerical and structural chromosome aberrations, including rare and not yet characterized abnormalities, abnormalities additional to specific rearrangements and complex defects. Although performed routinely, cytogenetic analysis is demanding in terms of time and experience and the quality of the results depends on the expertise of the laboratory.
To perform broad molecular screening in all acute leukemias and to avoid the need for many single RT-PCR reactions, Pallisgaard et al. 7 have developed a multiplex RT-PCR assay that allows simultaneous screening for 29 common fusion transcripts. A slightly modified version is commercially available (HemaVisiont). This has been validated mainly in ALL by several groups who retrospectively compared molecular to cytogenetic results. [7] [8] [9] [10] The goal of our study was to prospectively test the systematic use of broad molecular screening with a multiplex RT-PCR system and cytogenetics in a cohort of patients with acute leukemia in order to assess the impact of this strategy on diagnosis according to the WHO classification, genetic risk assignment and clinical management.
Patients and methods

Study design
This is a prospective cohort study of patients with acute leukemia. All consecutive patients referred for molecular diagnosis from four hematology centers were evaluated for genetic markers in [2000] [2001] [2002] [2003] 
Study population
The study involved 191 patients with acute leukemia. Five patients could not be evaluated because RT-PCR (failure of RNA extraction in one patient) or cytogenetics (no result in four patients) failed. The final analysis was restricted to 186 patients for whom both broad molecular screening and cytogenetics were available. Patient and disease characteristics are shown in Table 1 . The majority were AML (83%), 87% de novo and 13% at relapse; 17% had ALL. There were slightly more males than females (56 vs 44%) and only 6% of the patients were younger than 16 years old.
Cytogenetic analysis
Cell culture and chromosome preparation were performed on bone marrow or peripheral blood samples as reported previously. 11, 12 Chromosomes were stained in G-bands. Karyotypes were described according to the International System for Human Cytogenetic Nomenclature. 13 
Molecular analysis
RNA was extracted from whole blood or bone marrow samples using QIAamp RNA Blood Mini Kitt columns (QIAGEN) and multiplex RT-PCR for broad molecular screening was carried out with the HemaVisiont test (Bio RAD) according to the manufacturer's instructions. This qualitative multiplex RT-PCR system for molecular typing of leukemias detects 29 fusion transcripts (Table 2) , including more than 80 breakpoints or splice variants. Primers were designed to detect the most frequent types of MLL rearrangements. The system is based on a two-step procedure. In the first step, cDNA is used as a template in eight parallel nested multiplex PCR reactions. The PCR products are visualized on an ethidium bromide gel. Where a specific band in one of the eight multiplex reactions is present, a second defined set of multiplex nested RT-PCR is performed. The fusion transcript can be identified after gel electrophoresis according to the group of nested multiplex PCR to which it belongs and to its size. Each reaction contains an internal control reaction.
Classification
Broad molecular screening and cytogenetic results were classified independently as favorable, intermediate or unfavorable and risk assignments were compared.
For AML, broad molecular screening results involving the fusion transcripts AML1-ETO, CBFb-MYH11 or PML-RARa were considered to be of favorable risk. MLL rearrangements, AML1-MDS1-EVI1, DEK-CAN or BCR-ABL fusion transcripts were considered unfavorable. Negative broad molecular screening and other fusion transcripts were considered to be of intermediate risk. Cytogenetic results in AML involving t(8;21) (q22;q22), inv (16) Broad molecular screening and cytogenetic analysis S Meyer-Monard et al
For ALL, broad molecular screening results revealing a TEL-AML1 fusion transcript were considered favorable. BCR-ABL, MLL-AF4 and MLL-ENL fusion transcripts were classified as unfavorable. Negative broad molecular screening, an E2A-PBX1 fusion transcript and all other fusion transcripts were considered to be of intermediate risk.
14 Cytogenetic results with hyperdiploidy 450 without structure abnormality or a t(12;21)(p13;q22) were considered favorable. Hypodiploidy and t(9;22)(q34;q11), t(4;11)(q21;q23) and t(11;19)(q23;p13.3) were considered unfavorable. Normal karyotype, t(1;19) (q23;p13) and all other cytogenetic abnormalities were considered to be of intermediate risk and termed miscellaneous abnormalities.
14 Risk allocations from both approaches were compared to give a final risk assignment. In the case of a discrepancy, the method indicating the presence of a recurrent abnormality recognized by the WHO classification was regarded to be the most informative (e.g. AML1-ETO). In cases without a recurrent abnormality according to WHO, the method classifying the disease into a poorer risk category was retained. Detection of cryptic fusion transcripts determining prognosis was considered to overrule the karyotype.
Results
Distribution of abnormalities and genetic risk assignment
A genetic abnormality was detected in 120 out of 186 patients (65%) using cytogenetics or broad molecular screening or both. In all, 119 patients (64%) had an abnormal karyotype and broad molecular screening revealed a fusion transcript in 49 (26%). Broad molecular screening was positive in 40 (26%) patients with AML and in nine (30%) patients with ALL. Nine cryptic fusion transcripts were detected by broad molecular screening. An abnormal karyotype was found in 96 (62%) AML patients and 23 (74%) ALL patients. A complex karyotype was found in 48 of 186 patients (26%), most of whom (36) had a negative broad molecular screening. In all, 66 (35%) patients had negative results by both methods.
Broad molecular screening led to favorable risk assignment in 27 (14%, 26 AML and one ALL), to intermediate-risk assignment in 141 (76%, 116 AML and 25 ALL) and to unfavorable risk assignment in 18 patients (10%, 13 AML and five ALL). Cytogenetics led to favorable risk assignment in 24 (13%, all AML), to intermediate-risk assignment in 111 (60%, 84 AML and 27 ALL) and to an unfavorable risk assignment in 51 (27%, 47 AML and four ALL). Risk assignment was concordant in 148 (80%, 119 AML and 29 ALL) patients and discordant in 38 (20%, 36 AML and two ALL) ( Table 3 ). Final risk assignment was determined in four patients (2%) by broad molecular screening only and in 34 (18%) by cytogenetics only (Table 4) .
Results by WHO classification
Results are summarized in Table 3 .
AML with recurrent genetic abnormalities AML with t(8;21)/AML1-ETO was detected in all nine patients by both methods and these patients were considered favorable by both methods. However, cytogenetics revealed additional miscellaneous anomalies in five patients and complex abnormalities in two. One additional patient with t(8;21)/AML1-ETO detected by both methods and with complex abnormalities was included in the secondary AML category due to a history of prior myeloproliferative disorder.
AML with inv(16),t(16;16)/CBFb-MYH11 was diagnosed in seven patients. In six patients, broad molecular screening revealed the CBFb-MYH11 fusion transcript and cytogenetics the corresponding cytogenetic abnormality, leading to favorable genetic risk assignment by both methods. One patient had a normal karyotype and a cryptic CBFb-MYH11 fusion transcript and was, therefore, considered favorable by broad molecular screening but intermediate by cytogenetics. Cytogenetics revealed additional miscellaneous abnormalities in three patients and complex abnormalities in one.
AML with t(15;17)/PML-RARa was found in eight patients. Seven had the PML-RARa fusion transcript and the corresponding t(15;17) and were, therefore, considered favorable by both methods. One patient with a cryptic PML-RARa had trisomy 8 as sole cytogenetic anomaly and was considered intermediate by cytogenetics and favorable by molecular methods. Cytogenetics revealed additional miscellaneous abnormalities in two patients and complex abnormalities in two further patients. One additional patient with t(15;17)/PML-RARa detected by both methods and additional miscellaneous cytogenetic abnormalities was classified as secondary leukemia because of prior chemotherapy.
AML with 11q23/MLL was found in four patients. In two patients, broad molecular screening and cytogenetics were concordant. These patients had no additional karyotype abnormalities. Two MLL rearrangements were cryptic and detected by broad molecular screening only. Since one of these had complex abnormalities and the other monosomy 7, detection of these cryptic fusion transcripts did not change the genetic risk assignment, which was unfavorable by both methods.
AML with multilineage dysplasia
Among the 24 patients, 14 (58%) had a concordant genetic risk assignment. In all, 13 were intermediate and one unfavorable by both methods. No patient was favorable. Of the 13 patients with intermediate genetic risk assignment, the karyotype was normal in nine and miscellaneous abnormalities were present in four. The patient with unfavorable risk assignment had a DEK-CAN fusion transcript and an isolated t(6;9). The 10 patients (42%) with discordant genetic risk assignment had unfavorable disease by cytogenetics (one with inv(3), one with À7, one with tetrasomy 8 and complex abnormalities and seven with complex abnormalities). Broad molecular screening was negative in all cases.
Secondary AML
A total of 35 patients were diagnosed secondary AML. Out of 35 patients 25 had concordant results in terms of genetic risk assignment (71%, two favorable, 17 intermediate and six unfavorable). Of the two favorable patients, one presented a t(8,21)/AML1-ETO and complex abnormalities and one a t(15;17)/PML-RARa and miscellaneous abnormalities. The 17 intermediate cases all had a negative broad molecular screening. Of these, nine had a normal karyotype and eight had miscellaneous abnormalities. Of the six unfavorable patients, one had t(3;21)/AML1-MDS1, one t(9;11)/MLL-AF9, one t(11;19)/MLL-ELL, two t(9;22)/BCR-ABL and one BCR-ABL fusion transcript without corresponding t(9;22) but with complex abnormalities. All rearrangements were detected by broad 
Precursor T-ALL
Seven patients had a T-ALL. All were assigned to the intermediate genetic risk group by both methods. One had a cryptic SIL-TAL fusion transcript with complex abnormalities. The others were negative by molecular screening. Two of them had a normal karyotype and four a karyotype with miscellaneous abnormalities. Final risk assignment took into account assignment by both methods. In the case of concordant risk assignment, the final assignment was given by both methods. In the case of a discrepancy, the method indicating the presence of a recurrent abnormality recognized by the WHO classification was regarded to be the most informative (e.g. AML1-ETO). In cases without a recurrent abnormality according to WHO, the method assigning the disease into a poorer risk category was retained. Detection of cryptic fusion transcripts determining prognosis were considered to overrule the karyotype. Secondary AML BCR-ABL 44-45,XY,der(4)t(4;13)(p12;q14),del(5)(q13q33), der(5;15)(q10;q10),der(7),add(8)(p11),?add(10)(p?13), del(12)(p?) [9] ,-13,der(14;?)(q10;?),add(16)(q22) [4] , add(17)(p?) [2] ,À18,À21,+r [3] ,+2mar[cp10]
Precursor B-ALL E2A-PBX1 46,XX,del(9)(q?21.2q32),del(11)(p?11.2)?del(11)(q22q23) [6] /46,XX [11] Precursor B-ALL TEL-AML1 46,XX,t(?8;12)(q24;p13) [6] /46,idem,del(6)(q2?) [2] /46,XX [2] Precursor B-ALL MLL-ENL 47,XX,+X,inv(11)(p15q23) [10] Precursor T-ALL SIL-TAL 46,XY,der(9)del(9)(?q33q34)?inv(9)(q13q34) [4] /46,XY [10] Broad molecular screening and cytogenetic analysis S Meyer-Monard et al
Respective contribution of each method
Broad molecular screening revealed nine cryptic fusion transcripts (5%) ( Table 5) . Diagnosis according to WHO classification was changed in four patients by broad molecular screening. Detection of a cryptic CBFb-MYH11 fusion transcript permitted correct classification as AML with recurrent genetic abnormality in one, of a cryptic PML/RARa in one and of a cryptic MLL rearrangement in two patients (Table 3) . Broad molecular screening allowed correct genetic risk assignment in four patients. Two of them had an AML with recurrent abnormalities; one patient with cryptic CBFb-MYH11 and normal karyotype and one with cryptic PML-RARa with isolated trisomy 8 were mentioned before (Tables 3 and 5 ). In both cases, an intermediate-risk assignment by cytogenetics was corrected to a favorable risk assignment by broad molecular screening. The other two patients for whom genetic risk assignment was corrected by broad molecular screening had a precursor B-ALL. One had a cryptic TEL-AML1 fusion transcript and a karyotype with miscellaneous abnormalities, resulting in intermediate-risk assignment by cytogenetics that was corrected to a favorable risk assignment by broad molecular screening. The other patient had a cryptic MLL-ENL fusion transcript associated with a karyotype of miscellaneous abnormalities. This led to an intermediate-risk assignment by cytogenetics that was corrected to unfavorable by broad molecular screening. The two cryptic MLL rearrangements in the AML with recurrent genetic abnormalities did not alter the risk assignment since cytogenetic findings also led to an unfavorable assignment (Tables 3 and 5 ). Three cryptic fusion transcripts were found that did not change diagnosis or genetic risk assignment. These included BCR-ABL in a secondary AML (therapy related), E2A-PBX1 in a precursor B-ALL and SIL-TAL in a precursor T-ALL. Cytogenetic findings were abnormal in 71 (38%) patients with negative broad molecular screening. 48 of 49 patients with a positive broad molecular screening had an abnormal karyotype. 29 had abnormalities in addition to the fusion transcript and 12 of these were complex. Cytogenetic analysis did not change the diagnostic classification. Cytogenetics indicated an unfavorable genetic risk assignment of the disease in 10 patients with AML with multilineage dysplasia, in 10 patients with secondary AML and in 14 patients with AML not otherwise categorized. Cytogenetic analysis did not change the genetic risk assignments for ALL.
Discussion
Our data show that a combination of broad molecular screening and cytogenetic analysis of malignant cells is essential and can provide additional information for diagnosis, genetic risk assignment and follow-up of patients with acute leukemia.
Genetic risk assignment was carried out independently for each method using similar criteria. Cryptic fusion transcripts changed an intermediate-risk assignment to favorable or unfavorable in four patients and information gained from cytogenetics changed the genetic risk assignment from intermediate to unfavorable in 34 (18%). Cytogenetic analysis did not change risk assignment in AML with recurrent genetic abnormalities since all recurrent abnormalities were detected by broad molecular screening. However, assignment of patients with AML with multilineage dysplasia, secondary AML and AML not otherwise categorized mostly benefited from a cytogenetic contribution. Cytogenetics gave information relevant to genetic risk assessment more often than broad molecular screening and it was clearly essential in cases of negative molecular screening.
Our results demonstrated that cytogenetics cannot be replaced by molecular methods.
Diagnosis according to WHO was corrected to AML with recurrent genetic abnormality in four patients (2%) by detection of a cryptic fusion transcript. In two of these, detection of the cryptic fusion transcript also corrected genetic risk assignment from intermediate to favorable. Even though cytomorphology and immunophenotype in some cases may suggest the presence of a fusion transcript, overlooking these cryptic fusion transcripts could lead to overtreatment of a patient with a CBFb-MYH11 fusion transcript and omission of all-trans-retinoic acid and suboptimal treatment in a PML-RARa-positive patient. Cytogenetic analysis did not change diagnostic classification.
Treatment decisions, such as timing of stem cell transplantation or intensification of chemotherapy, is based increasingly on genetic prognostic characteristics of the leukemia. [15] [16] [17] Our results show that the use of broad molecular screening or cytogenetics alone would have led to incorrect assignment of genetic risk group in 20% of patients, with direct consequences for treatment strategy. Cytogenetics influences treatment decisions by conferring unfavorable risk assignment on patients with negative broad molecular screening. Broad molecular screening, however, influences treatment decisions by revealing cryptic fusion transcripts. In total, a cryptic fusion transcript was found in 5% of leukemias. This rather low number speaks in favor of the quality of modern cytogenetic examination. Detection of a cryptic fusion transcript might change genetic risk assignment but most important it could be a target of specific therapy. In our study population, we found one PML/ RARa and one BCR-ABL among nine cryptic fusion transcripts.
The presence of a fusion transcript provides a unique tool for monitoring minimal residual disease by quantitative RT-PCR during follow-up. In our cohort, 26% of patients had a fusion transcript accessible for molecular monitoring.
Cytogenetics reveals rough chromosomal abnormalities and gives global information about genetic alterations, whereas molecular screening only detects targeted, submicroscopic genetic lesions. Therefore, the two methods provide complementary information about the genetic status of a cell. Of the nine cryptic fusion transcripts found in our study population, two are known to be cryptic (SIL-TAL, TEL-AML1). The karyotypes corresponding to the other seven cryptic fusion transcripts are usually readily detectable. Quality of a cytogenetic preparation was good in all of them. Thus, these seven cases (4%) can be regarded as being unexpected, real cryptic fusion transcripts.
The prognostic value of additional karyotype abnormalities to a recurrent abnormality in AML with t(8;21)/AML1-ETO, inv(16)/ CBFb-MYH11 or t(15;17)/PML-RARa has been variously appreciated.
14 Large retrospective studies, such as those presented by Byrd et al. 5 and Grimwade et al. 6 support the hypothesis that additional abnormalities do not alter the favorable prognosis of t(8;21)/AML1-ETO, inv(16)/CBFb-MYH11 and t(15;17)/PML/ RARa abnormalities. These studies are most widely used as a reference for risk assessment in clinical trials. 18 Further clarification of the prognostic value of additional genetic abnormalities in cases with a recurrent fusion transcript will increase the clinical relevance of cytogenetics.
An up-front combined broad molecular screening and cytogenetic analysis is time-and cost effective. The broad molecular screening system used is less time consuming than repeated series of RT-PCR and covers a wide spectrum of wellknown fusion transcripts. Since our molecular test system does not reveal all MLL rearrangements, FISH plays an important role in their detection. Cytogenetics could suggest the implication of Broad molecular screening and cytogenetic analysis S Meyer-Monard et al a given gene in a genetic aberration whereas the broad molecular screening used will only do so if the genetic aberration leads to one of the 29 fusion transcripts. FISH, however, can readily show the involvement of specific genes in genetic aberrations independent of their partner genes. Of the patients, 58% were assigned an intermediate genetic risk with the combined molecular and cytogenetic approach. This group of patients is a mixture of those at real intermediate risk and others who may have favorable or unfavorable risk. In the future, we will need more information relating to prognosis of rare cytogenetic alterations. New molecular markers may define more clearly the risk status of these patients 19 and could be integrated into future molecular tools that resemble the present broad molecular screening method. Furthermore, gene expression profiles might give new information on the genetic risk of patients classified so far as intermediate.
In conclusion, both broad molecular screening and cytogenetics are essential and provide complementary information for diagnosis, treatment and follow-up of patients with acute leukemia. The contribution of each method differs according to the leukemia subtype. Conventional cytogenetics cannot be replaced by broad molecular screening. The comparison of genetic risk assignment provided by broad molecular screening or cytogenetics defines their respective roles in the diagnosis and management of acute leukemia. This approach may be useful as a benchmark for measuring the effectiveness of new molecular tools such as genetic profiling.
